Sponsors › The Cleveland Clinic

The Cleveland Clinic

Every GLP‑1 and incretin trial, approval and scheduled result we hold for The Cleveland Clinic, drawn from ClinicalTrials.gov and Drugs@FDA.

The Cleveland Clinic is an academic or hospital sponsor, not a drug company with 8 trials in the incretin class on file here, across 3 molecules. The programme is split between 2 early-stage trials and 6 in phase 3 or later. The next scheduled result is 2026-12-31.

Molecules

liraglutide · semaglutide · tirzepatide

Trials on file

8

Active trials

5

Results scheduled

2

Approved FDA submissions

0

Results due

Trials on file

All 8 incretin trials recorded for this sponsor, active first.